OCLMCR | ISSN: 3067-7130 | Volume 2 Issue 3 Review Article |

Neurodegenerative Diseases and Pivotal Therapies

Ehtesham Suhail¹, Mujtaba Suhail², Minhua Zhou³ and Suhail Rasool³*

¹Princeton University, Princeton, NJ, USA
²Dr. Ronald E. McNair Academic High School, 123 Coles St, Jersey City, USA
³Suninflam Inc., 3289 Berryessa Street, Suite 3, Palo Alto, CA, USA

*Corresponding Author: Suhail Rasool; Suninflam Inc. 3289 Berryessa Street, Suite 3, Palo Alto, CA, 94303, USA

DOI: 10.64258/3067-7130.2026.1020043

Submission Date: March 27, 2026

Published Date: April 9, 2026

Treatments for neurodegenerative diseases are increasingly shifting away from purely symptomatic management—such as levodopa for Parkinson’s disease and cholinesterase inhibitors for Alzheimer’s disease—toward molecule-specific, disease-modifying therapies. Emerging approaches include immunotherapy targeting protein aggregation (amyloid-beta, tau, and α-synuclein), gene therapy, CRISPR-based genome editing, nanotechnology-assisted drug delivery across the blood–brain barrier, and microglial cell replacement therapies. Both active and passive immunization strategies are being developed to reduce the accumulation of toxic proteins responsible for neurodegeneration. Additionally, gene therapy and RNA editing techniques aim to correct genetic mutations, such as those seen in Huntington’s disease, with RNA-based editing offering a potentially reversible alternative to permanent DNA modification. Currently, treatment options for Alzheimer’s disease include NMDA receptor antagonists like memantine and cholinesterase inhibitors such as donepezil and rivastigmine, while Parkinson’s disease is commonly managed with MAO-B inhibitors and dopamine precursors like levodopa.

Neurodegenerative Disease, Therapies, Astrocytes, Microglia

Ehtesham Suhail, Mujtaba Suhail, Minhua Zhou, Suhail Rasool (2026) Neurodegenerative Diseases and Pivotal Therapies. On J Clin & Med Case Rep 2(3): 1-20. DOI: 10.64258/3067-7130.2026.1020043.